Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Activist Investor Calls For Sanity As FTC Rejects Grail-Illumina Deal

Executive Summary

Illumina faces a difficult decision now that the US FTC has formally rejected its attempt to re-acquire Grail, the sequencing company it originally sold in 2016. The FTC and European regulators say the merger would stifle competition but the company plans to appeal the ruling.

You may also be interested in...



FTC’s Khan Addresses PBMs, Amgen-Horizon Merger, At Contentious Congressional Hearing

Republican members of the House Judiciary Committee question FTC policies under Khan’s leadership, including its challenge of the Amgen-Horizon and Illumina-Grail mergers, as well as a proposal to require more information in pre-notification submissions. ‘You’re a bully,’ Representative Issa tells her.

CEO Resignation Raises Doubts About Illumina’s Commitment To Grail

Francis deSouza resigned as CEO and chairman of Illumina just a few weeks after winning the support of shareholders. General counsel Charles Dadswell will take over as interim CEO.

Illumina Appeals FTC Decision, Grail Swings And Misses

Illumina has formally appealed the FTC’s decision to block its acquisition of Grail, just days after Grail mistakenly sent letters to patients suggesting they could have cancer.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel